These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 8101967)

  • 1. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 3. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 300-Hz subthalamic oscillations in Parkinson's disease.
    Foffani G; Priori A; Egidi M; Rampini P; Tamma F; Caputo E; Moxon KA; Cerutti S; Barbieri S
    Brain; 2003 Oct; 126(Pt 10):2153-63. PubMed ID: 12937087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal ganglia oscillations and pathophysiology of movement disorders.
    Rivlin-Etzion M; Marmor O; Heimer G; Raz A; Nini A; Bergman H
    Curr Opin Neurobiol; 2006 Dec; 16(6):629-37. PubMed ID: 17084615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the functional significance of primate retinal dopamine receptors.
    Bodis-Wollner I; Antal A
    J Neural Transm Suppl; 1995; 45():67-74. PubMed ID: 8748611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R; Greenamyre JT
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of dopamine D1 and D2 receptors in the basal ganglia of PTZ kindling model of epilepsy: effects of angiotensin IV.
    Tchekalarova J; Sotiriou E; Angelatou F
    Brain Res; 2004 Oct; 1024(1-2):159-66. PubMed ID: 15451378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J; Dougherty JJ; Nichols RA
    J Neurochem; 2006 Jul; 98(2):481-94. PubMed ID: 16805841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right-left asymmetry of D1- and D2-receptor density is lost in the basal ganglia of old rats.
    Giardino L
    Brain Res; 1996 May; 720(1-2):235-8. PubMed ID: 8782918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociating the cognitive effects of levodopa versus dopamine agonists in a neurocomputational model of learning in Parkinson's disease.
    Moustafa AA; Herzallah MM; Gluck MA
    Neurodegener Dis; 2013; 11(2):102-11. PubMed ID: 23128796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.